Head-to-head evidence
CagriSema vs Tirzepatide: REDEFINE 4 Head-to-Head Weight-Loss Results
A source-backed CagriSema vs tirzepatide comparison covering the REDEFINE 4 head-to-head trial, the missed non-inferiority endpoint, estimands, and claim limits.
"CagriSema versus tirzepatide" has become one of the most searched obesity-drug match-ups, partly because the two candidates posted similar-looking weight-loss headlines and partly because, in February 2026, Novo Nordisk released results from REDEFINE 4, a rare open-label trial that tested the two directly against each other. That trial changes the conversation: instead of comparing percentages from separate studies, there is now one randomized comparison to read carefully.
This guide separates what the head-to-head trial actually showed from the cross-trial numbers people quote, and it explains why a "23% versus 25.5%" line is more nuanced than it looks. For molecule basics first, see the cagrilintide peptide guide and the tirzepatide guide.
The short version: in the only direct comparison so far, CagriSema produced strong weight loss but did not meet its goal of matching tirzepatide. Everything else is context that keeps that result honest.
Evidence Snapshot
| Common claim | Evidence picture | Boundary |
|---|---|---|
| CagriSema and tirzepatide are basically the same drug. | CagriSema pairs an amylin analogue (cagrilintide) with a GLP-1 receptor agonist (semaglutide). Tirzepatide is a single molecule acting at GIP and GLP-1 receptors. | Different receptor targets mean trial results from one cannot simply be copied onto the other. |
| CagriSema beat tirzepatide head-to-head. | In the open-label REDEFINE 4 trial, CagriSema produced about 23.0% weight loss versus 25.5% for tirzepatide 15 mg over 84 weeks. | The trial did not meet its primary endpoint of non-inferiority, so CagriSema was not shown to match tirzepatide on weight loss. |
| A 22.7% vs 22.5% comparison proves they are equal. | REDEFINE 1 (CagriSema) and SURMOUNT-1 (tirzepatide) were separate trials with different designs, populations, and durations. | Comparing top-line percentages across different trials is not a valid head-to-head result. |
| These results validate research-market blends. | All numbers come from defined, monitored investigational products in randomized trials. | Trial data does not certify an unapproved vial, a compounded mix, or a do-it-yourself stack. |
| CagriSema is already approved because trials are done. | Novo Nordisk announced a US FDA submission in December 2025 with a decision anticipated in late 2026. | A submission and top-line announcements are not approval, and any final label must be read when available. |
Two Different Drugs, Not Two Doses Of One
CagriSema and tirzepatide are easy to lump together because both are once-weekly injections that drive large weight loss, but the mechanisms differ. CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist. Tirzepatide is a single molecule that activates both the GIP and GLP-1 receptors.
That means CagriSema works through amylin biology plus GLP-1 signaling, while tirzepatide works through GIP plus GLP-1 signaling. The pathways overlap in appetite and gut-hormone effects but are not identical. The incretin and amylin comparison walks through these receptor differences in more depth.
You cannot transfer a safety or efficacy claim from one to the other. A tirzepatide result does not describe CagriSema tolerability, and a CagriSema number does not predict tirzepatide outcomes. That is why a direct trial matters more than any pile of separate study percentages.
What REDEFINE 4 Actually Showed
REDEFINE 4 (trial record NCT06131437) was an 84-week, open-label Phase 3 trial that randomized 809 adults with obesity and one or more weight-related conditions, at a mean starting weight of about 114 kg. One group received CagriSema (cagrilintide 2.4 mg with semaglutide 2.4 mg); the other received tirzepatide 15 mg. Both were once-weekly subcutaneous injections.
According to Novo Nordisk's February 2026 announcement, CagriSema produced about 23.0% mean weight loss compared with 25.5% for tirzepatide 15 mg over 84 weeks. Despite the strong absolute result, the trial did not meet its primary endpoint: it failed to demonstrate that CagriSema was non-inferior to tirzepatide on weight loss. In plain terms, CagriSema was not shown to match tirzepatide in this comparison.
Two design points deserve attention. First, the study was open-label, meaning participants and investigators knew which drug was being given; that design can influence behavior and expectations and is generally considered weaker than a blinded trial. Second, this is a top-line company announcement, not a peer-reviewed publication. The full data set, statistical detail, and safety tables should be read when the trial is published and presented in full.
On tolerability, Novo described the most common adverse events as gastrointestinal and mostly mild to moderate, easing over time, consistent with the GLP-1 class. That is a summary, not a label, and it does not settle uncommon events or individual risk.
Why The "22.7% vs 22.5%" Comparison Misleads
Before REDEFINE 4, most comparisons relied on separate trials. CagriSema reported about 22.7% mean weight loss in REDEFINE 1, a 68-week trial in adults with obesity without diabetes. Tirzepatide reported up to about 22.5% weight loss at the 15 mg dose in SURMOUNT-1, a 72-week obesity trial. The numbers look almost identical, which is why they get quoted side by side.
But these were different studies with different participants, durations, comparators, and analysis rules. A placebo-controlled trial answers a different question than a head-to-head trial. Matching headline percentages across separate studies is not evidence that two drugs perform the same; only a direct comparison like REDEFINE 4 can address that, and there CagriSema came in numerically lower.
The picture also shifts by population. REDEFINE 2 studied CagriSema in adults with type 2 diabetes and reported smaller weight reduction than REDEFINE 1, which fits the broader pattern that people with diabetes often lose less weight on these drugs. Population matters as much as molecule, so a single percentage rarely travels well between groups.
Reading The Two Sets Of Numbers
Modern obesity trials usually report results under more than one estimand, and the headline you see depends on which one is quoted. The "if all adhered" or efficacy estimand estimates what happens if participants stayed on treatment as intended. The "treatment regimen" estimand reflects real-world adherence, including people who stop or reduce dose.
In REDEFINE 4, the efficacy-style figures were roughly 23.0% for CagriSema versus 25.5% for tirzepatide, while real-world adherence figures were reported lower for both arms. The gap between the two drugs persisted under either lens. When a marketing page or forum post quotes only one percentage, it is worth asking which estimand it came from, because efficacy estimands tend to look larger than what an average person might experience.
None of these numbers should be read as a personal forecast. Trial averages come from selected, monitored populations with protocolized dose escalation and support. Individual results vary widely, and discontinuation, side effects, and adherence are part of the real outcome, not footnotes.
Status, And How To Read The Claims
As of this publication date, CagriSema is investigational in the United States. Novo Nordisk submitted CagriSema to the FDA in December 2025 based on REDEFINE 1 and REDEFINE 2, with a decision anticipated in late 2026. Tirzepatide is FDA-approved for chronic weight management as Zepbound and for type 2 diabetes as Mounjaro, so the two are at different regulatory stages. A submission is not an approval, and any future CagriSema label should be read directly when it exists.
The comparison also has a research-market shadow. Online sellers describe "CagriSema" as if it were simply cagrilintide and semaglutide powders mixed together, sometimes alongside tirzepatide stacking instructions. FDA has stated that cagrilintide cannot be used in compounding under federal law and has warned about non-FDA-approved GLP-1 products, misleading sameness claims, and research-labeled vials sold for human use. Trial data on defined investigational products does not certify any of those products.
Where that leaves things: in the one direct comparison so far, tirzepatide produced numerically greater weight loss and CagriSema missed its non-inferiority goal, though CagriSema still drove large weight loss. Both findings come from rigorous programs, but the strongest single result is still a top-line announcement awaiting full publication. For broader class context, see retatrutide vs tirzepatide vs semaglutide and the dedicated cagrilintide and CagriSema evidence guide.
References
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1), New England Journal of Medicine / PubMed.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2), New England Journal of Medicine / PubMed.
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine / PubMed.
- CagriSema demonstrated 23% weight loss in head-to-head REDEFINE 4 trial; primary endpoint not achieved, Novo Nordisk company announcement.
- REDEFINE 4: CagriSema versus tirzepatide trial record (NCT06131437), ClinicalTrials.gov.
- A Study of Tirzepatide in Participants With Obesity or Overweight (SURMOUNT-1, NCT04184622), ClinicalTrials.gov.
- Once-weekly cagrilintide for weight management in people with overweight and obesity, The Lancet / PubMed.
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity, Current Obesity Reports / PubMed.
- FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs, U.S. Food and Drug Administration.
- Q1 2026 investor presentation, Novo Nordisk.
Disclaimer
This page is educational and is not medical advice. It does not provide dosing, injection, compounding, reconstitution, stacking, sourcing, storage, weight-loss treatment, diabetes treatment, or individualized medical guidance for cagrilintide, CagriSema, semaglutide, tirzepatide, or related products. Medication decisions should be made with qualified healthcare professionals using current regulator-reviewed labels and official safety information.
Next steps
Continue with the closest guide, peptide profile, or research tool.
